six

Athletes at the heart

09 July 2025 - After the Olympic Agenda reforms pledged to put athletes front and centre, we explore how the past…

7 months ago

Para Snow Sports classification: Part 1 Research and collaboration to ensure fair competition

Jul 04, 2025 - Learn about all aspects of the classification process across Para Alpine, Para Cross-Country and Para Snowboard in…

7 months ago

Wisdom of Happiness to be Shown at the 78th Cannes Film Festival

Wisdom of Happiness, a documentary about the Tibetan Buddhist spiritual leader the Dalai Lama, will be shown at the 78th…

8 months ago

FOOD, FLAVOR AND FESTIVITIES: WORLD FOOD & MUSIC FESTIVAL 2025 VENDORS ANNOUNCED

GREATER DES MOINES, Iowa, July 2, 2025 /PRNewswire/ -- The World Food & Music Festival presented by Veridian Credit Union has…

8 months ago

HUTCHMED to Announce 2025 Half-Year Financial Results

July 03, 2025 04:30 ET  | Source: HUTCHMED (China) Limited HONG KONG and SHANGHAI and FLORHAM PARK, N.J., July 03,…

8 months ago

Yili Secures Four World Dairy Innovation Awards at the 18th Global Dairy Congress

AMSTERDAM, June 23, 2025 /PRNewswire/ -- On June 18–19, the Global Dairy Congress 2025 was held in Amsterdam. At the forum,…

8 months ago

Addex Therapeutics Reports Q1 2025 Financial Results and Provides Corporate Update

June 19, 2025 01:00 ET  | Source: Addex Therapeutics Strong cash position of CHF2.8 million at end of Q1 2025GABAB…

8 months ago

Sunrise Group Recognized 6th among ICIS 2025 Global Top 100 chemical distributors

NEW YORK, June 17, 2025 /PRNewswire/ -- Sunrise Group has once again demonstrated its industry leadership, securing a spot among…

8 months ago

Roche to advance prasinezumab into Phase III development for early-stage Parkinson’s disease

Results from Phase IIb PADOVA and longer term follow-up data suggest clinical benefit on top of symptomatic treatment in early-stage…

8 months ago

[Ad hoc announcement pursuant to Art. 53 LR] Roche provides safety update on Elevidys gene therapy for Duchenne muscular dystrophy in non-ambulatory patients

After a thorough clinical review, the benefit-risk for the use of Elevidys in non-ambulatory patients with Duchenne has been re-assessed,…

8 months ago